| Autor: |
Nilius, Verena, Killer, Madeleine C., Timmesfeld, Nina, Schmitt, Melina, Moll, Roland, Lorch, Anja, Beyer, Jörg, Mack, Elisabeth, Lohoff, Michael, Burchert, Andreas, Neubauer, Andreas, Brendel, Cornelia |
| Zdroj: |
OncoImmunology; May 2018, Vol. 7 Issue: 5 |
| Abstrakt: |
ABSTRACTSurvival of patients with germ-cell cancer (GCC) and primary progression or relapse after cisplatin-based first-line chemotherapy is highly heterogeneous, ranging from close to zero to more than 70%. We investigated β-1,4-Galactosyltransferase-I (B4GALT1) expression levels in peripheral lymphocytes in a cohort of 46 testicular cancer patients. B4GALT1enhances immune cell crosstalk via glycosylation of surface molecules. A high expression level of B4GALT1in T-lymphocytes, but not in monocytes, was associated with a lower risk of relapse with a hazard ratio (HR) of 0.66 (95% confidence interval (CI) of HR: 0.45-0.97; p= 0.02) upon multivariate Cox regression analysis. Correspondingly, interleukin 10 (IL10), a cytokine released by cytotoxic T-cells, was likewise significantly elevated in T-lymphocytes of non-relapse GCC patients (HR: 0.3; 95% CI of HR: 0.14-0.65; p= 0.002). Our data indicate that glycosylation and activation of T-lymphocytes may play a pivotal role in disease control in GCC patients with primary progressive or relapsed disease. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
